Matt Hoffman

The first biosimilar to the approved formulation of natalizumab is indicated for relapsing forms of MS and for induction/maintenance of remission in adults with Crohn disease.

The oral calcitonin gene-related peptide receptor antagonist is now indicated for prevention in both episodic and chronic migraine.